Year: 2019
Type: article
Abstract: Mental disorders are common and represent a significant and worldwide public health concern (Smith, 2011;Vigo et al., 2016;Patel et al., 2018).The global burden of disease due to mental illness accounts for 21-32% of years lived with disability and 7-13% of disability-adjusted life-years (Vigo et al., 2016).The Lancet commission on global mental health and sustainable development just recently estimated a loss of US$16 trillion to the global economy due to mental disorders in the period 2010 -2030(Patel et al., 2018)).Psychotherapy and pharmacotherapy are the two key available treatments presently offered to millions of subjects with mental disorders around the world.However, recent evidence suggests that their effects are overestimated due to several factors, such as publication bias, researcher allegiance, and other shortcomings in study design (Ioannidis, 2005(Ioannidis, , 2008;;Driessen et al., 2015;Tajika et al., 2015;Cuijpers et al., 2016; Leichsenring et al., 2017;Leucht et al., 2017;Cuijpers et al., 2019;van Os et al., 2019).Thus, the true efficacy of psychotherapy and pharmacotherapy remains contested.Meta-analyses or systematic reviews of randomized controlled trials (RCTs) are considered to provide the highest level of evidence (1a) (Oxford Centre, 2009).Both meta-analyses and RCTs, however, may differ with regard to the strictness of testing treatment efficacy, depending, for example, on the comparator against which the treatment is tested.Whereas comparisons to waiting list or no-treatment can at best show that a treatment is better than doing nothing, comparisons with treatment as usual (TAU) or placebo show whether treatments have an additional gain compared to TAU or placebo.They also provide information on whether the efforts, costs, and possible side effects of specialized treatments pay off from a health-economic perspective.Thus, these comparisons provide better estimates of the true efficacy of a treatment (Cuijpers et al., 2016).Recent high-ranking meta-analyses suggest that the efficacy of psychotherapy and pharmacotherapy in comparison to placebo or TAU is limited.For key mental disorders such as depressive disorders (Driessen et al., 2015;Cipriani et al., 2018;Cuijpers et al., 2019), anxiety disorders (Heeren et al., 2015;Curtiss et al.,
Source: Psychological Medicine
Language: English
Subfield: Clinical Psychology
Field: Psychology
Domain: Social Sciences
Keywords: mental illness, psychotherapy, pharmacotherapy, treatment efficacy, placebo response, usual care, publication bias, meta-analysis, randomized controlled trials, depressive disorders, anxiety disorders, schizophrenia, bipolar disorder, schizophrenia spectrum disorders, psychosis spectrum disorders, bipolar spectrum disorders, psychosis, treatment-resistant depression, treatment-resistant schizophrenia
Open Access status: bronze
Funder: Gemeinsame Bundesausschuss
OpenAlex ID: W2972040771
